The source of dietary fat influences anti-tumour immunity in obese mice
July 25, 2025 / obesity and cancer / dietary fat types / tumor immunity / butter vs palm oil / anti-tumor metabolism
In obese mice, saturated fats from butter or beef tallow accelerate tumor growth by impairing anti-tumor immunity, while fats like palm or olive oil do not—highlighting dietary fat source as a modifiable factor in cancer risk.
New research uncovers gut microbe-derived metabolites as potential therapy for obesity-related metabolic disorders
July 28, 2025 / gut microbiome / obesity therapy / tryptophan metabolites / GLP-1 hormone / metabolic health
Gut microbe-derived indole, a tryptophan metabolite, restores hormone-secreting gut cells lost in obesity, improving insulin secretion and appetite regulation—offering a potential microbiota-targeted therapy for metabolic disorders.
Valley Health Earns Reaccreditation Through the American College of Surgeons’ Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP)
July 28, 2025 / bariatric surgery / obesity treatment / surgical accreditation / patient outcomes / MBSAQIP
Valley Health has earned reaccreditation from MBSAQIP, affirming its high standards in bariatric surgery and commitment to improving outcomes for patients with obesity-related conditions through evidence-based, safe, and effective surgical
How Metabolic Health Impacts Cancer Risk, Progression, and Therapy Response
July 22, 2025 / metabolic health / cancer progression / obesity and cancer / insulin resistance / oncology care
Metabolic dysfunction—including obesity, insulin resistance, and inflammation—promotes cancer development and impacts therapy response. Integrating metabolic health strategies into oncology care may improve outcomes through lifestyle interventions, pharmacologic tools, and multidisciplinary support.
Extreme childhood obesity drives liver and diabetes risks
July 22, 2024 / pediatric obesity / metabolic syndrome / insulin resistance / liver disease / childhood diabetes
Extremely severe pediatric obesity is rising in the U.S. and is strongly linked to insulin resistance, MASLD, and metabolic syndrome, emphasizing the urgent need for targeted public health interventions and equitable access to anti-obesity therapies.
Tirzepatide Tops TRT for Men With Hypogonadism and Obesity
July 23, 2025 / tirzepatide therapy / metabolic hypogonadism / obesity treatment / testosterone levels / erectile dysfunction
Tirzepatide outperformed testosterone replacement therapy in men with obesity-related hypogonadism, improving weight loss, testosterone levels, and erectile function—offering a metabolic-first approach to treating functional hypogonadism without suppressing the hypothalamic-pituitary-gonadal axis.
Predictive markers of obesity and glucose metabolism dysfunction in adult common marmosets (Callithrix jacchus)
July 25, 2025 / marmoset obesity / glucose metabolism / HbA1c biomarker / body mass index / metabolic dysfunction
In adult marmosets, early peak body weight, increased fat mass, and elevated BML strongly predicted glucose metabolism dysfunction, including high HbA1c. These findings support using BML and %fat as early markers of obesity-related metabolic risk.
15 regions chosen for groundbreaking effort to reduce cardiovascular disease
July 28, 2025 / cardiovascular disease / CKM syndrome / collaborative care / public health initiative / heart disease prevention
The American Heart Association’s CKM Health Initiative targets 15 U.S. regions to improve care for interconnected conditions—cardiovascular, kidney, metabolic diseases—through screening, treatment, and collaborative care models, aiming to reduce heart disease and stroke risk in over 250,000 patients.
Liupao tea improves metabolic syndrome risks in clinical trial
July 23, 2025 / Liupao tea / metabolic syndrome / blood pressure reduction / gut microbiota / cholesterol improvement
Liupao tea improved blood pressure, cholesterol levels, body composition, and gut microbiota in adults with metabolic syndrome, supporting its role as a safe, cost-effective functional beverage—though further controlled trials are needed to confirm its clinical utility.
Association of serum total antioxidant capacity and uric acid with obesity and cardiometabolic traits in Mexican children
July 26, 2024 / childhood obesity / oxidative stress / uric acid levels / insulin resistance / cardiometabolic risk
In Mexican children, both serum total antioxidant capacity (sTAC) and uric acid (SUA) levels are elevated in obesity and correlate with insulin resistance, blood pressure, and lipid changes, suggesting oxidative stress markers may indicate cardiometabolic risk based on weight status.
Tirzepatide ‘important choice’ for increasing testosterone in metabolic hypogonadism
July 24, 2025 / tirzepatide benefits / metabolic hypogonadism / testosterone therapy / erectile dysfunction / male fertility
Tirzepatide significantly increased testosterone levels, improved body composition, and enhanced erectile function in men with metabolic hypogonadism, outperforming testosterone replacement and lifestyle changes alone, and potentially offering a fertility-preserving alternative to traditional hormone therapy.
Vida Health Appoints Leading Industry Executives to Accelerate Growth in Cardiometabolic Care
July 23, 2025 / Vida Health growth / cardiometabolic care / obesity management / GLP-1 solutions / virtual healthcare
Vida Health appointed two seasoned executives to scale its personalized obesity and cardiometabolic care platform, following a major capital raise. The move supports expanded GLP-1 prescribing, payer partnerships, and sustainable growth in evidence-based virtual care.
Guideline-directed medical strategies for the co-management of heart failure and metabolic dysfunction-associated steatotic liver disease
July 28, 2025 / MASLD management / heart failure care / metabolic dysfunction / cardiometabolic disease / multidisciplinary approach
Metabolic dysfunction-associated steatotic liver disease (MASLD) and heart failure share pathophysiological roots and often coexist. This review calls for integrated, guideline-directed strategies to co-manage both conditions, emphasizing multidisciplinary care to improve outcomes and mitigate cardiometabolic disease burden.
60% of Liver Cancer Are Preventable, Report Reveals
July 28, 2025 / liver cancer prevention / MASLD awareness / obesity and cancer / hepatitis B vaccination / metabolic liver disease
Up to 60% of liver cancer cases are preventable, with rising rates linked to obesity and MASLD. The Lancet Commission urges global action on viral hepatitis, alcohol use, and metabolic health to curb liver cancer incidence and mortality.
Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH
July 22, 2025 / Madrigal Pharmaceuticals / MASH treatment / Rezdiffra funding / metabolic liver disease / biopharma financing
Madrigal Pharmaceuticals secured $500 million in non-dilutive funding from Blue Owl Capital to advance its MASH pipeline, including the launch of Rezdiffra and support for ongoing trials, reinforcing its leadership in treating metabolic dysfunction-associated steatohepatitis.
15 U.S. Regions Selected for Initiative to Combat Cardiovascular-Kidney-Metabolic Syndrome
July 28, 2025 / ‘CKM syndrome care / cardiovascular health / metabolic disease / American Heart Association / chronic disease initiative
The AHA’s Cardiovascular-Kidney-Metabolic Health Initiative will transform care in 15 U.S. regions, addressing CKM syndrome through coordinated care, evidence-based therapies, and community support to improve outcomes for over 250,000 patients facing heart, kidney, diabetes, and obesity-related conditions.
Alcohol-related liver disease has more than doubled in the last 20 years
July 23, 2025 / alcohol-related liver disease / metabolic syndrome / liver disease risk / heavy drinking trends / public health intervention
Alcohol-related liver disease has more than doubled over 20 years, with rising risk among women, older adults, low-income individuals, and those with metabolic syndrome—despite stable national alcohol consumption—highlighting the need for targeted screening and intervention.
Increased serum uric acid to creatinine ratio is associated with metabolic dysfunction associated steatotic liver disease
July 24, 2025 / MASLD biomarker / uric acid ratio / hepatic steatosis / liver disease screening / metabolic dysfunction
Elevated serum uric acid to creatinine ratio (SUA/SCr) is independently associated with the severity and future risk of MASLD. This ratio may serve as a noninvasive biomarker for early detection and monitoring of hepatic steatosis progression.
The impact of parity on the risk of nonalcoholic fatty liver disease defined by hepatic steatosis index: A nationwide cohort study
July 24, 2025 / NAFLD risk / parity and liver disease / reproductive health / premenopausal women / hepatic steatosis index
In this nationwide Korean study, parity was associated with a lower risk of NAFLD in premenopausal women after adjusting for confounders like obesity. No significant association was found in postmenopausal women, highlighting reproductive factors’ influence on liver health.
New study could help doctors address diabetes, prediabetes
July 24, 2025 / low-gluten diet / gut microbiota diversity / microbiome health / gluten-free risks / dietary impact
A sustained low-gluten diet in healthy adults significantly reduced gut microbiota diversity and altered microbial composition over time, suggesting potential long-term risks to gut health in individuals without gluten-related disorders.